or Try an Advanced Search...

    Antibody Drug Conjugate Stocks List

    Symbol Grade Name % Change
    TGTX A TG Therapeutics, Inc. 3.26
    ACLX B Arcellx, Inc. 3.93
    PYXS C Pyxis Oncology, Inc. 12.18
    MRSN D Mersana Therapeutics, Inc. 0.78
    KPTI D Karyopharm Therapeutics Inc. -0.61
    GMAB F Genmab A/S -0.13
    CLDX F Celldex Therapeutics, Inc. -0.94
    ADCT F ADC Therapeutics SA 0.00
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
    Related Stock Lists: Cancer Medicine Biotechnology Clinical Medicine Monoclonal Antibodies Solid Tumors Immunology Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Clinical Development Immunotherapies Lymphoma Biopharmaceutical Camidanlumab Tesirine Cancer Treatment Cd20 Chemotherapy Drugs Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Antibody Drug Conjugate stocks.

    Symbol Grade Name Weight
    CNCR C Loncar Cancer Immunotherapy ETF 5.55
    CANC C Tema Oncology ETF 4.67
    SBIO A ALPS Medical Breakthroughs ETF 4.17
    IDNA B iShares Genomics Immunology and Healthcare ETF 3.85
    FBT A First Trust Amex Biotech Index Fund 3.22
    View all Antibody Drug Conjugate ETFs...
    Compare ETFs
    Compare CANC to SBIO Compare CNCR to IDNA Compare CNCR to SBIO

        Antibody Drug Conjugate Stocks Recent News

        Date Stock Title
        Nov 8 ADCT ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
        Nov 8 ACLX Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
        Nov 8 ACLX Arcellx GAAP EPS of -$0.48, revenue of $26.03M
        Nov 8 KPTI Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
        Nov 8 CLDX Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 8 GMAB High Growth Tech Stocks To Watch In November 2024
        Nov 7 ACLX Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
        Nov 7 ACLX Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
        Nov 7 ADCT ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
        Nov 7 ADCT ADC Therapeutics Non-GAAP EPS of -$0.28, revenue of $18.46M misses by $0.04M
        Nov 7 ADCT ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
        Nov 7 TGTX TG Therapeutics, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
        Nov 7 ACLX Arcellx price target raised to $106 from $81 at Morgan Stanley
        Nov 7 ACLX Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
        Nov 7 CLDX Celldex GAAP EPS of -$0.64 beats by $0.04, revenue of $3.19M beats by $2.13M
        Nov 7 GMAB Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...
        Nov 6 CLDX Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
        Nov 6 CLDX Celldex: Q3 Earnings Snapshot
        Nov 6 CLDX Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
        Nov 6 GMAB Genmab Announces Financial Results for the First Nine Months of 2024
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
        Related Stock Lists: Cancer Medicine Biotechnology Clinical Medicine Monoclonal Antibodies Solid Tumors Immunology Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Clinical Development Immunotherapies Lymphoma Biopharmaceutical Camidanlumab Tesirine Cancer Treatment Cd20 Chemotherapy Drugs Genetics
        Antibody Drug Conjugate

        An Antibody Drug Conjugate (ADC) is a type of targeted therapy used to treat cancer. It is a combination of an antibody, which is a protein that binds to a specific target on cancer cells, and a drug, which is a chemical that kills the cancer cells. The antibody is linked to the drug, allowing it to be delivered directly to the cancer cells. This targeted approach reduces the side effects of traditional chemotherapy, which can damage healthy cells as well as cancer cells.

        Browse All Tags